Jones David Scott
Insider CIK 1779458 · EYPT SVP & Chief Commercial Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-02-09 | 2024-02-13 | 4,967 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-02-09 | 2024-02-13 | 5,000 | — | $0 | 5,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-02-09 | 2024-02-13 | 5,000 | — | $0 | 48,572 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-02-09 | 2024-02-13 | 4,967 | — | $0 | 43,572 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-02-09 | 2024-02-13 | 1,955 | $28.80 | $56.3K | 46,617 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-02-09 | 2024-02-13 | 1,701 | $28.80 | $49.0K | 44,916 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-02-02 | 2024-02-05 | 209 | — | $0 | 4,375 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-02-02 | 2024-02-05 | 209 | $28.49 | $6.0K | 37,962 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-02-02 | 2024-02-05 | 209 | $11.47 | $2.4K | 38,171 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-26 | 2024-01-29 | 9,604 | — | $0 | 8,721 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-26 | 2024-01-29 | 16,413 | — | $0 | 68,742 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-26 | 2024-01-29 | 16,413 | $25.45 | $417.7K | 47,566 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-26 | 2024-01-29 | 9,604 | $12.90 | $123.9K | 47,566 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-26 | 2024-01-29 | 9,604 | $25.27 | $242.7K | 37,962 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-26 | 2024-01-29 | 16,413 | $3.26 | $53.5K | 63,979 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-25 | 2024-01-26 | 300 | — | $0 | 18,325 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-25 | 2024-01-26 | 300 | — | $0 | 85,155 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-25 | 2024-01-26 | 300 | $25.00 | $7.5K | 38,262 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-25 | 2024-01-26 | 300 | $3.26 | $978 | 38,562 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-25 | 2024-01-26 | 300 | $12.90 | $3.9K | 38,262 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-25 | 2024-01-26 | 300 | $25.00 | $7.5K | 37,962 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-24 | 2024-01-26 | 5,700 | — | $0 | 85,455 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-24 | 2024-01-26 | 5,600 | — | $0 | 18,625 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-24 | 2024-01-26 | 5,600 | $25.01 | $140.1K | 37,962 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-24 | 2024-01-26 | 5,600 | $12.90 | $72.2K | 43,562 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-24 | 2024-01-26 | 5,700 | $25.01 | $142.6K | 43,562 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-24 | 2024-01-26 | 5,700 | $3.26 | $18.6K | 49,262 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-23 | 2024-01-24 | 400 | — | $0 | 24,225 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-23 | 2024-01-24 | 500 | — | $0 | 91,155 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-23 | 2024-01-24 | 400 | $12.90 | $5.2K | 38,362 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-23 | 2024-01-24 | 500 | $25.00 | $12.5K | 37,962 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-23 | 2024-01-24 | 400 | $25.00 | $10.0K | 38,462 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-23 | 2024-01-24 | 500 | $3.26 | $1.6K | 38,862 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-22 | 2024-01-24 | 5,416 | — | $0 | 4,584 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-22 | 2024-01-24 | 28,750 | — | $0 | 31,250 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-22 | 2024-01-24 | 28,750 | $10.13 | $291.2K | 66,712 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-22 | 2024-01-24 | 28,750 | $22.69 | $652.3K | 37,962 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | S Sale | 2024-01-22 | 2024-01-24 | 5,416 | $22.24 | $120.5K | 66,712 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-22 | 2024-01-24 | 5,416 | $11.47 | $62.1K | 72,128 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2024-01-06 | 2024-01-09 | 15,285 | — | $0 | 30,570 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2024-01-06 | 2024-01-09 | 15,285 | — | $0 | 42,109 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2024-01-06 | 2024-01-09 | 4,147 | $20.40 | $84.6K | 37,962 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2024-01-05 | 2024-01-09 | 21,000 | — | $0 | 21,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2024-01-05 | 2024-01-09 | 42,000 | — | $0 | 42,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-06-20 | 2023-06-22 | 45,855 | — | $0 | 45,855 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-02-09 | 2023-02-13 | 4,967 | — | $0 | 4,967 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2023-02-09 | 2023-02-13 | 5,000 | — | $0 | 10,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2023-02-09 | 2023-02-13 | 1,473 | $4.17 | $6.1K | 25,133 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2023-02-09 | 2023-02-13 | 1,483 | $4.17 | $6.2K | 26,606 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-02-09 | 2023-02-13 | 4,967 | — | $0 | 23,089 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2023-02-09 | 2023-02-13 | 5,000 | — | $0 | 28,089 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2023-01-06 | 2023-01-10 | 91,655 | — | $0 | 91,655 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2022-02-28 | 2022-03-02 | 4,105 | — | $0 | 0 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2022-02-28 | 2022-03-02 | 1,130 | $9.95 | $11.2K | 15,599 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2022-02-28 | 2022-03-02 | 4,105 | — | $0 | 16,729 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2022-02-09 | 2022-02-11 | 60,000 | — | $0 | 60,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2022-02-09 | 2022-02-11 | 4,966 | — | $0 | 9,934 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2022-02-09 | 2022-02-11 | 15,000 | — | $0 | 15,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2022-02-09 | 2022-02-11 | 1,473 | $10.13 | $14.9K | 12,624 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2022-02-09 | 2022-02-11 | 4,966 | — | $0 | 14,097 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2021-11-01 | 2021-11-03 | 10,000 | — | $0 | 10,000 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2021-06-22 | 2021-06-23 | 14,900 | — | $0 | 19,005 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2021-06-22 | 2021-06-23 | 60,300 | — | $0 | 60,300 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2021-02-28 | 2021-03-02 | 4,105 | — | $0 | 4,105 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2021-02-28 | 2021-03-02 | 1,702 | $10.81 | $18.4K | 7,380 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2021-02-28 | 2021-03-02 | 4,105 | — | $0 | 9,082 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise deriv | 2020-06-30 | 2020-07-02 | 41,050 | — | $0 | 82,100 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | F Tax w/h | 2020-06-30 | 2020-07-02 | 14,060 | $0.76 | $10.7K | 26,990 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | M Exercise | 2020-06-30 | 2020-07-02 | 41,050 | — | $0 | 41,050 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2020-02-28 | 2020-03-03 | 123,150 | — | $0 | 123,150 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2020-02-28 | 2020-03-03 | 246,250 | — | $0 | 246,250 | SEC↗ |
| EYPT EyePoint Pharmaceuticals, | A Award deriv | 2019-06-10 | 2019-06-12 | 350,000 | — | $0 | 350,000 | SEC↗ |